“GENOMIDS”

A Mini Project Submitted In

Partial Fulfillment of the
Requirements for the Degree of

Masters of Business Administration

By

SONALI AGRAHARI
SAWAN DUBEY
(Semester -1st)
Under the supervision of
Dr. TINU KAUR
Associate professor

To the
KNIPSS, Management Institute, Sultanpur, UP, India
Dr. A.P.J. Abdul Kalam technical university (AKTU)(formally UPTU),
Lucknow(UP), INDIA 2023

1
 Certificate of originality

We hereby declare that this mini project-1 report is our own work and that, to the
best of my knowledge and belief, it reproduces no material previously published or
written that has been accepted for the award of any other degree or diploma, except
where due acknowledgement has been made in text.

(Sonali Agrahari)

Enrollment no.

(Sawan Dubey)

Enrollment no.

Date

2
 Certificate

This is to certify that Miss Sonali Agrahari and Mr. Sawan Dubey MBA (2022-

23Batch) are students of KNIPSS, management institute has undertaken the Mini

Project-1 on “GENOMIDS”

The project has been carried out by the student in partial fulfillment of the

requirements for the award of MBA, under my guidance and supervision.

I am satisfied with the work of Mr. Sawan Dubey and Miss Sonali Agrahari.

Date:

Academic Mentor’s Name: Dr. TINU KAUR Mam

(Signature)

……………………

3
 ACKNOWLEDGMENT

We offer my sincere thanks and humble regard in KNIPSS, MANGEMENT

INSTITUTE, By AKTU University Lucknow for importing me very valuable
professional project in MBA.

We pay our gratitude and sincere regards to My HOD Ma’am DR. INDERJEET
KAUR for giving me this wonderful opportunity. We would like to thank my
project guide DR. TINU KAUR for giving me the cream of knowledge. We are
thankful to her as she has been given a constant source of advice, motivation and
inspiration. We are also thankful to her for giving suggestion and encouragement
throughout the project work.

We take opportunity to express my gratitude and thanks to our computer lab staff
for providing me opportunity to utilize their resources for the completion of the
project.

We are also thankful to my family and friends for constantly motivating us to

complete the project and providing us an environment which engaged my
knowledge.

Sonali Agrahari

Sawan Dubey

MBA-1st SEMESTER

4
 CONTENT

 INTRODUCTION 123

 INDUSRIAL FRAMEWORK 123

 MISSION AND VISSION 123

 DETAILED DESCRIPTION 1234

a. RESEARCH AND DEVELOPMENT/ AWARENESS

b. FINANCE PLANNING

c. PRODUCTION PLANNING

d. SALES AND MARKETING PLANNING

 SWOT ANALYSIS

 CONCLUSION AND FUTURE ENHANCEMENTS

 REFRENCES

5
 Chapter-1

INTRODUCTION

1. What is genomids?

Genomids is combination of gene and medicines. In this product we will combine the
gene of the person with the medicines. This medical product is revolutionary and
different in the world. This will made up of powerful DNA to solve the rare and common
diseases. Genomids is a platform for the people who are facing the problem of rare
diseases. Our company will work on the rare diseases and common diseases in a
economic way.
The population is increasing rapidly day by day and by the cause of environmental
problem people are suffering with rare diseases and this problem is just not limited to old
age people this also include the infants baby now. Our company Genomids are try to
solve this problem economically with a view to change the world. Our company is like
modern solution for the modern problem of the world.
This business plan will show that how a total investment of only Rs. 1cr. could generate
the revenue of Rs. 5cr in two years.
The purpose of this plan is to secure additional funding from bank to cover the start-up
costs.
Genomids is a startup which people love to add with, it has social cause as well as first
mover advantage
Genomids is similar term with genomics and we can say the work and field of study of
both are almost same because genomics are studied for the maintaining and
understanding the evolution and protect our biological ecosystem. Same as our company
try to understand the rare and common cause of problems in medical field to find the
different economical solution

2. Why it is necessary?
Genomids is for the person who does not have strong financial background and facing the rare
problems. The companies who offer the rare medicines for the treatment is only affordable by
richer family of the society but huge problems are faced by middle and lower class of the society.

Our company targeted the group of middle and lower class of the world. Like for the cure of
expensive medicine the revolutionary product Generic medicine are made, we are also trying o
made this product as the replacement for expensive treatments.

6
Human and animals genetics have different shades it means we have wide scope for finding the
cure for the problems. As per research of scientists, human body have cure for the problems the
they are facing and this will also apply with the case of animals. So as conclusion we want to say
genomids help the people who are facing rare diseases with their parental gene because are rare
diseases is genetic disorder and it will only solve with their genes and heredity.

We will just not only deal with rare disorders but we also try to solution of common diseases
which we are facing every year. Genomids does not only start for profit making, our first priority
is to solve the problem economically and get benefit for both (company and society).

3. Genomics with Genomids

In the modern world we have the advance technologies to solve our problems so we are using
genomics technology to solve the problems and start our business.

A Genomics technology study the 24000 chromosome of human body to identify the evolution
of the ecosystem of human, this will help them to identify the solutions that they can get to cure
unknown diseases this same rule follow with the animals, genomics try to understand the every
possible way to tackle the problem. The diseases we are facing inner self have solution in inner
self too.

Genomids tie up with reputed genomics research center to form the company and help the
society. Our advantage is that we are first one who will personalized the medicines for our
patients with their parental or generational gene. As well as we will also work on common
problems like flu, cancer, covid and other common diseases.

The combination of genomics and genomids are will take medical sector on new heights. The
research of genomics is two or three decade old which means it has expertise of accuracy and
standard of defining problems or solutions. The modern technology of genomics and the core
planning of Genomids will create storm in world. Initially it will different for mindset of society
but slowly they will understand the need of this.

The percentages of people died every year due to rare disease are increasing every year. Rare
diseases explain 4.2% of general population Years of Life Lost (YLLs), comparing to 1.2%
attributable to infectious diseases and 2.6% to diabetes mellitus.

WHO’s Global Health Estimates provide the latest available data on causes of death and
disability globally, by WHO region and country, by age, sex and by income group.
These estimates are produced using data from multiple sources, including national vital
registration data, latest estimates from WHO technical programmes, United Nations partners and
inter-agency groups, the Global Burden of Disease and other scientific studies. Before

7
publishing, the GHE are reviewed by WHO Member States via consultation with national focal
points and WHO country and regional offices.

Top 10 global causes of disability-adjusted life years

Top 10 global causes of death in 2019 (DALYs) in 2019

1. Ischaemic heart disease

1. Neonatal conditions
2. Stroke
2. Ischaemic heart disease
3. Chronic obstructive pulmonary
3. Stroke
disease
4. Lower respiratory infections
4. Lower respiratory infections
5. Diarrheal diseases
5. Neonatal conditions
6. Road injury
6. Trachea, bronchus, lung cancers
7. Chronic obstructive pulmonary disease
7. Alzheimer disease and other
8. Diabetes mellitus
dementias
9. Tuberculosis
8. Diarrheal diseases
10. Congenital anomalies
9. Diabetes mellitus
10. Kidney diseases

Graphical representation of death rate with rare diseases

8
 Chapter-2
Industrial framework
Genomids is a new player in the medical sector. Genomids start with creating awareness about
our work and services we offer which we will discuss later in R and D topic. We will open an
online portal for giving information about the work we did and how to contact with us. Our head
office will be in Lucknow and we separate doctor team to advice the patients about their
diseases, causes, precautions and most importantly treatments under their budget.

Genomids creates a friendly and pleasant environment for our potential customers. This business
plan calls for an exciting, profitable as well as socialist start-up years ahead with its futuristic
growth as we meet the demands of the community. In all, this plan describes a healthy company
with good growth prospects, looking to manage its orderly growth near future.

Genomids will work on three points at a time:

1. DOCTORS
2. MEDICAL INSTITUTES
3. CERTIFICATIONS

1. DOCTORS: Our first step will be to tie up with the doctors who recommend us to the
patients who deal with rare diseases and help us to set up a medical awareness about our
work and diseases

2. MEDICAL INSTITUTIONS: As we know it we are dealing with medical products we

should do tie ups with medical institutions which provide help us to grow combined.

3. CERTIFICATIONS: Certification for any product is important especially when it comes

to medical product it is our prior concern to take certification from respective authorities
to make people believe that we are genuine and trustable company.

This type of steps makes our company unique and that’s how we make our brand
genomids.

 Different from others

9
 Our difference and uniqueness make us separate and relatable to public in
compare to our competitor. As we have different concept about our product and
work but still people can think that we are same as our competitors therefore, we
are try to create different and unique image of ourselves in mind of society.

We are using their genes to cure their disease and this is our USP. We will also
deal in common diseases factor to make our company relevant in every medical
concern our objective does not limit in India but make our identity to whole world
and tie up with international bodies to make our strong identity.

Chapter-3

Mission and vision

Genomids mission is to offer users economical medical treatments and best experience
with our services. We are committed to providing the service quality and value that our
users expect.
Genomids creates pleasant and friendly atmosphere for patients in well-designed and
productive environment in which people can work happily. We are very sensitive
towards quality of our products that we give to our patients. We are focusing on majorly
urban cities where most of the middle class family lived and then as year passes we will
focus on village areas.
After covering the whole India our mission is to make tie up with other major countries
too. Our main product will be common medicines which people want like for covid or
flue and subsidiary product will be rare diseases medicines for both we will market
separately
.
This will create psychology in people’s mind that we are good in both medical fields and
we can get great profit and customers from both the sides. Our mission of capture Indian
medical market will complete with in 3-4 years if we follow this policy.

Our customers have main concern of health so our vision is improve our service and
work quality day by day to gain our customer’s trust. And our vision is clear that we will
follow the cockroach policy of startup it means we will try to slow and steady growth
and improve our standard day by day and we will give more than 100%. Our investors
get profit with steady growth.

10
 We see our company on top in coming 5 years. We will use strategy, staff and system to
provide each customer with seamless experience through working in the field.

1. We will work in two line where one we manufacture and supply the
genetic medicine of common diseases to capture common market of
medical with economical price.

2. Researches for common diseases is one time investment where we work

one time on studying about causes and solutions with genes and get
benefit for long time through supply.

3. Secondly, we will work on rare diseases especially research on people

who have it and try to solve with their genetics or with their parental
genes this will help us deal with the problem

4. Our one line is business to business work and other line is business to
customer work. We will work on both at same time but with separate
team.

5. We will first target urban cities and developing cities then we will also
capture rural areas and through their feedback we will improve day by
day.

6. We will try to generate positive cash flow from operations, and at least
40% net profits to sales.

Our vision is to become first choice for patients and also for companies who want tie up with
us – as measured by our users, our employees, our stakeholders and the community we live in.

Our values are critical to our success. They are strong foundations of GENOMIDS define who
we are and set up apart from our competitors. They underline our vision of our future.

These values include

1. Performance excellence. We act like responsible owners, always seeking to meet or

exceed expectations.

2. Teamwork. We act as team, committed to each other, and bound by trust and loyalty.

11
 3. Integrity. We treat one another, and all our stakeholders with dignity and respect.
Honestly, ethical behavior and integrity are fundamental characteristics of our business
conduct.

Chapter-4

Detailed Description Of The Idea

This detailed description is the study of following:

 Awareness and Research and development of product

 Financial planning

 Production planning

 Sales and Marketing planning

Research And Development/Awareness

 On the world level

Genomics is the study of genetic information (the genome), its roles, and its complex
interactions. The language of DNA is common to living organisms. Knowledge developed for
one organism is therefore directly relevant to other organisms across the plant and animal
kingdoms, including humans.
Genomics and its related disciplines have profoundly transformed the study of living organisms.
They provide a unique level of understanding that already contributes broad applications to
improve the quality of human life, Canada's economy, and environmental sustainability.
Genomics leads a true scientific revolution and applications keep breaking new grounds. Many
share the opinion that genomics will be for the 21st century what information technology was for
the 20th century, with massive performance increases that will continue for years to come.
Genes are just one part of a vast and largely unresolved system. What also matters is the way
networks of genes function together in a given environment. Computer technology,
nanotechnology and other sciences converge with biology to provide a powerful array of new
transformative technologies and explore research questions that were recently still out of reach.

12
Genomics-driven innovations are finding solutions to complex challenges related to living
organisms. They are also raising questions of societal and economic importance. By being at the
forefront of research in genomics, federal laboratories support innovation and decisions based on
credible and dependable scientific evidence.

A rapidly evolving field

Genomics is continuously redefining its own frontiers and relies on techniques that evolve
quickly. A first genomics revolution has seen the genomes of a large number of living organisms
fully sequenced, including the human genome completed in 2003.
Genomics research has then entered a second revolution with developments in speed, accuracy
and effectiveness of DNA sequencing and computer power at reduced cost. For example,
sequencing of the first draft human genome had cost $3 billion. Now it can cost less than $1K.
Sequencing generates colossal quantities of data, requiring the development of novel statistical
and informatics approaches to analyze these sequences and understand their roles in living
organisms. The field of genomics is thus shifting towards 'Big data' analysis coupled with high-
performance computing.
Transformative advances keep emerging, such as:

 whole-genome sequencing;
 USB drive-sized sequencers;
 novel techniques for the assembly of genomes;
 detailed measurements at the level of a single cell;
 synthetically created DNA;
 large-scale gene expression datasets allowing powerful investigations of gene function;
 powerful analytical processes;
 gene editing techniques based on Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)

Gene editing in particular has seen an explosion in its use, including in mammalian cells. This is
opening the door for gene correction therapies in humans and precise targeted modifications in
virtually any organism.
The current generation of genomics not only includes research on genomes, but also converging
sciences and disciplines that generate powerful new tools and accelerate the rate of discovery and
practical innovation. While massive performance increases and transformative developments will
continue for years to come, genomics has already evolved from an information science to an
applied field that has profound societal and economic impacts.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global
genomics market is projected to grow at a promising rate from 2021 to 2031 (forecast period).
Genomics has scientifically shown its capabilities in preventing, administering, and treating
diseases. The healthcare environment is increasingly transitioning away from traditional methods

13
of treatment and toward precision medicine, and this change has been steered in recent years by
extraordinary clinical properties.
Whole genome sequencing has evolved as a valuable method for the diagnosis of crucial
disorders such as cancer. According to the National Cancer Institute, by 2040, the number of new
cancer cases is expected to rise by 29.5 million, while cancer-related fatalities will rise by 16.4
million. The requirement for vast amounts of DNA data to be stored, sequenced, and analyzed
has opened the way for novel products and software. Such factors are projected to boost the
global genomics market during the forecast period.
Genomics Market – Competitive Landscape
Key players operating in the global genomics market are F. Hoffmann-La Roche Ltd.
(Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific (US), Agilent
Technologies, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), and BGI (China).
Request Brochure of Report -
Key players are actively acquiring and forming joint ventures with other companies in order to
solidify their market positions around the world. For instance, Illumina (US) partnered with
Helix OpCo (US) in 2021 to strengthen the national surveillance infrastructure in the US to
monitor the onset and incidence of emerging strains of SARS-CoV-2. The combination of
Illumina's sequencing technology and experience, as well as Helix's nationwide COVID-19
testing coverage, will greatly enhance the country's existing surveillance efforts to identify and
characterize new SARS-CoV-2 variants.
Genomics Market – Trends and Opportunities
Strong investment in genomic research & development is one of the key factors projected to
drive the global genomics market growth over the forecast period. The adoption of
groundbreaking technology in genetics is primarily drawing investments in genomics. These
investments assist global genomics institutes and organizations in developing individualized
medications and therapeutics to treat incurable diseases and adopt therapies.

Furthermore, rising government expenditure in genomics research and development is likely to

boost the global genomics market in the coming years. For example, the Government of Iceland
and deCODE genetics have collaborated to perform coronavirus demonic analysis. Similarly, the
Government of India is assisting HaystackAnalytics in researching virus transmission by genome
sequencing techniques. The expanding number of startups and similar initiatives is expected to
drive the global genomics market in the future years.
Moreover, COVID-19 had a favorable impact on the genomics market. Researchers attempted to
resolve genetic intensity and vulnerability to coronavirus infection using existing genetic
datasets. Genome-wide association studies (GWAS) and multi-omic-based techniques have been
employed to identify the common variants underpinning biological networks and host-pathogen
interactions. Additionally, data obtained from genomes, such as polygenic risk scores (PRS) and
ABO blood classes, can be used to decode COVID-19 vulnerability, difficulties, and tolerance.
In addition, biobanks that connect genomic data to electronic health records can be used to
investigate the impact of genomic factors on the clinical course of COVID-19 patients.
Genomics Market – Regional Landscape

14
The North America genomics market is projected to grow during the forecast period. Increased
government initiatives, precision medicine innovation, and the rapid adoption of new sequencing
technologies are projected to drive genomics market growth in North America.
Europe is expected to make considerable contributions to the genomics market growth.
Increasing adoption of sequencing technologies and increased funding for research programs in
nations such as the United Kingdom are projected to help the regional market expand in the
future years.
Asia Pacific genomics market is anticipated to experience significant growth during the forecast
period. Diverse countries, including China, India, and Vietnam, are boosting the demand for
genomic sequencing as a result of various research programs. Moreover, due to increased
demand for genetic sequencing and testing in China and advancements in bioinformatics, the
genomics market in Asia Pacific is expected to witness a consider

able growth rate.

15
Above both the diagrams shows that how much peoples died every year due to diseases. The
awareness of genomics importance are taking serious by every country so now as an Indian we
also want to represent Indian genomics company that is genomids. We are also planning for
common disease genetic medicines to capture the market.

16
  On India level
Government of India are also planning researces for genomics and finding best possible resouces
to update genomics field in india.

Current State of Genetic Testing

Genetic testing in India has evolved in leaps and bounds in the past decade. Currently, there exist
DNA-based tests that address multiple concerns in healthcare, from disease prevention to
molecular diagnosis (In the case of preventive healthcare, genetic tests estimate the lifetime risk
of disease, predisposition to biological traits and health parameters (. They also analyze a
person’s response to drugs in terms of efficacy and risk for adverse reactions. These tests are
primarily used as screening tools for establishing an effective strategy to reduce disease risk,
delay, or avoid symptoms and manage existing conditions. Diagnostic genetic tests, on the other
hand, help in identification of the molecular cause of the disease. These tests are used to confirm
known or suspected diagnosis, carrier status determination, identification of at-risk genetic
relatives, optimize treatments, and clinical decision. There are different types of diagnostic
genetic tests currently available in India such as single-gene and multigene testing, exome, and
genome sequencing, carrier and newborn screening. Other types of tests include those which
assess reproductive risk, such as prenatal testing and preimplantation genetic diagnosis.

Challenges and Limitations

Understanding the need of the patient is the key for determining the right genetic test. The
biggest hurdles faced by clinicians are genetic data interpretation, finding genetic links for
complex conditions, and lack of actionable genetic information. In certain cases of complex
conditions, such as cancer, an array of genetic tests might be ordered to determine the genetic
cause.However, no findings may come to light, thus posing a challenge for the patient and the
clinician. The accuracy and precision of genetic tests lies in the translation of genetic findings
into clinical outcomes. In the absence of information on genotype-phenotype correlations,
genetic test results might be inconclusive.

Genetic Data Interpretation for Indian Patients

Genetic diagnosis via clinical sequencing (e.g., genome-, exome-, single-, or multi-gene) is the
front-line test recommended for many inherited diseases. Establishing the genetic cause of
disease is vital for patient care and treatment, and hence clinical findings must be reported with
high precision and accuracy. All clinical reporting protocols are required to adhere to standards
set by American College of Medical Genetics (ACMG), for proper classification of variants and
subsequent disclosure to patient/clinician. As per ACMG guidelines, in order to differentiate
benign and pathogenic variants, a detailed study of the variant’s clinical significance is required.

17
This includes multiple criteria such as variant frequency, location in or near the gene, mechanism
of said gene, effect of variant on protein domain or function, hotspot, or nearby mutations if any,
etc. Apart from these, evidence of the variant having caused the disease in patients with similar
clinical phenotype is essential to establish pathogenicity.

Financial planning

Genomic medicine capabilities

As already discussed, India is a highly diverse heterogenous country, and as a result genomic
medicine could have transformative potential. With decreasing infant mortality rates, genetic
disorders are emerging as an important group of diseases. India is home to about one-third of all
rare diseases, and according to a 2021 report by the Ministry of Health and Family Welfare, the
number of diseases in India that are globally recognised as rare diseases may encompass from
around 7,000 to 8,000 disorders. The Organization of Rare Diseases in India reports that around
1 in 20 individuals in India is affected by a rare disorder.
However, recording of rare disease in India is mostly collected from tertiary care hospitals, and
information is limited. Moreover, the lack of diversity and focus on Western populations in
global genome databases is another obstacle to securing reliable and robust data. In India,
projects like the Thalassemia Screening and Counselling Centre at the Red Cross Society
National Headquarters are targeting inherited rare disease and providing genetic testing and
counselling services for specific cases.

Direct to consumer testing is a rapidly growing industry in India. Genetics tests such as single-
gene, multi-gene, exome and genome sequencing, carrier and new-born screening, prenatal
testing and preimplantation genetic diagnosis are all available – for a price. Genetic tests can cost
anywhere between 3,000-100,000 INR. According to Dr V L Ramprasand, CEO of MedGenome,
“In the initial years, we had to go from one specialist doctor to another to convince them of the
possibilities of genomic testing. In the initial years till 2016-17 period, we could do hardly 500-
600 tests. Now we do over 10,000 genetic tests a month”.
However, one area of concern is the lack of regulatory oversight to monitor the use of genetic
tests, and companies that offer direct-to-consumer testing can market their services without
regulation. This lack of oversight is concerning as genetic counselling and proper interpretation
of results are essential to ensure individuals are properly educated and informed about what

18
results mean. Moreover, risk factors may be overstated, and inappropriate treatment, be that
prescriptions or recommended lifestyle changes, may result in other problems and unnecessary
stress.

The future genomics landscape

The future genomics landscape in India is promising. The genomics and pharmaceutical sector
has already seen enormous growth in the past few years, with a 200% increase in foreign
investment in 2020-21, according to The Economic Survey. While presenting the new Union
Budget for 2022, Finance Minister Nirmala Sitharaman identified genomics as a key “sunrise”
opportunity, and announced that the government will bring about policies that support and
bolster domestic capacities for genomic medicine.
To encourage genomics investment, the government will promote thematic funds which blend
private and public finances, with Nirmala Sitharaman saying, “Supportive policies, light-touch
regulations, facilitative actions to build domestic capacities and promotion of research &
development (R&D) will guide the government’s approach. For R&D in these sunrise
opportunities, in addition to efforts of collaboration among academia, industry and public
institutions, government contribution will be provided.”

Our first motive is to take advantage of government finance benefits then we tie up with other
institutions as per our requirements. We will also look foe venture capitalists who invest in our
idea.

Production planning
The Department of Biotechnology (DBT) initiated the ambitious “Genome India Project” (GIP)
on 3rd January 2020. The GIP aims to collect 10,000 genetic samples from citizens across India,
to build a reference genome. This is no mean feat, given that the genome contains all the genetic
matter in an organism, i.e., the complete set of DNAs.
Whole-genome sequencing and subsequent data analysis of the genetic data of these 10,000
individuals would be carried out. This would aid our understanding of the nature of diseases
affecting the Indian population, and then ultimately support the development of predictive
diagnostic markers. This is a landmark initiative, particularly because it would bring valuable
addition to existing genome research, which has so far been limited to the Western context. It
allows India to draw upon its tremendous genetic diversity, given the series of large migrations
historically, and thus, add greatly to the current information about the human species.
Through whole-genome sequencing, the plan is to build an exhaustive catalogue of genetic
variations for the Indian population. This would aid in the designing of genome-wide association
chips which will facilitate further large-scale genetic studies in a cost-effective manner.
Furthermore, it would also open new vistas for advancing next-generation personalized

19
medicine in the country, paving the way for predicting health and disease outcomes and
modulating treatment protocols based on the genome sequences. The initiative would also
support the development of targeted preventive care, as it has the potential to help identify those
population groups which are more susceptible to various risk factors for certain diseases. For
instance, if a region shows a tendency towards a specific disease, customized interventions can
be made in the region, accordingly, leading to more effective treatment overall.

So as per the government plan we also were planning the same pattern of research and produce
the wholesome product for the Indian market first. The production work starts when the study of
genomics sample complete. We will dedicate our doctor’s team for one year study work to get
clear and positive result. As soon as we will complete our work of research for rare diseases we
well further look for solutions for common diseases.

We will hire voluntary peoples who want to help us in this work. We will study their gene and
also experiment on them as per their capabilities. After the complete certification of our work
will start production of medicines.

Sales and marketing planning

The global genomics market size was valued at USD 24.16 billion in 2021 and is projected to
witness a compound annual growth rate (CAGR) of 16.4% from 2022 to 2030. The growth of
genomics market is attributed to factors such as the growing demand for gene therapy,
personalized medicine, drug discovery, and an increased incidence of cancer cases across the
globe. Moreover, increasing number of joint ventures and partnerships amongst market players
are also expected to have a positive impact on the genomics market growth. For instance, in June
2022, Illumina, Inc., and Allegheny Health Network, signed into a collaboration for effective
evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage
patient care.

20
The COVID-19 pandemic outbreak had posed challenges to applications of genomics in terms of
research and therapeutics. Nevertheless, some niche applications were of great use to mankind
during the pandemic situation to facilitate immediate attention for designing effective
diagnostics, effective therapeutics and steps to curb the spread of COVID-19. For example, the
viral genome mutational rate (~1-2 bases per month) was gauged for the validity of PCR cycle
was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the
vaccine development process was streamlined.
Many genomic surveillance programs were launched country wise to understand the dynamics of
the pandemic situation and to effective preventive measures. For instance, in December 2020, the
Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of
Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the
genomic variations in the SARS-CoV-2 by sequencing technologies.
The increasing prevalence of inheritred cancers is expected create a high demand for cancer
genomics. The substantial understanding of human genome have targeted focus on use of various
gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas
gene technology. For instance, in September 2022, a group of researchers at the University of
California introduced the applications of precision genome editing agents for management of
inherited retinal diseases (IRDs).
Furthermore, the growth of the genomics market is attributive to the extensive research,
development strategies carried out by the biopharmaceutical companies for drug discovery and
advancements in technology enabled personalized medicine. For instance, in August 2022,
researchers at the Clemson University launched an open-source model that is designed to aid
researchers build prediction models to represent extensive cellular interactions and allow for the

21
integration of large datasets for personalized medicine applications like drug-matching for cancer
therapeutics.
The market players are extensively working towards collaborations, expansions, acquisitions and
huge capital investments to advance research in genomics to understand rare diseases and to aid
drug discovery. For instance, PacBio declares a collaboration with the Genomics England society
for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders.
The study is intended to re-sequence a selection of samples collected during Genomics
England’s 100,000 genomes project to discover potential operational and clinical benefits of
long-read sequencing for the identification of mutations associated with rare diseases.
Technology & Application Insights
The functional genomics segment dominated the overall market with the largest revenue share of
31.9% in 2021. The dominance of the segment can be attributed to research studies aiming to
understand a particular phenotypical expression of a given disease condition. Many gene
therapies for cancers are designed on the basis of functional genomics. For instance, in June
2020, researchers at European Molecular Biology Laboratory (EMBL) at Heidelberg increases
the scalability and precision metrics of functional genomics CRISPR/Cas9 gene-based screens
through targeted single-cell RNA sequencing. Single-cell RNA sequencing gives deep insights
into levels of gene expression in individual cells and can capably analyze CRISPR/Cas9
functional genomics screens.
The biomarker discovery segment is expected to witness a substantial growth rate over the
forecast period owing to the favorable outcomes and the level of efficacy offered by genomics in
numerous diagnostic applications. Researchers across the globe are identifying novel biomarkers
that could capably suggest a disease condition like a specific type of cancer. For instance, in
September 2022, researchers at the University of Cincinnati published their research on
biomarkers that could capably predict breast cancer progression and could be potential targets for
new treatments. They discovered that the oncogenes called Ron and DEK can regulate certain
metabolites that accelerate the growth of cancer cells.

22
Deliverables Insights
The product segment dominated the market and accounted for a revenue share of 69.5% of the
market in 2021. The products used in genomics are broadly segmented into two categories—
instruments or systems that are required for the synthesis and sequencing of the nucleic acid
sequences. The increase in preference for personalized medicines and decline in sequencing
costs owing to the launch of NGS technology resulted in the development of novel products or
systems. The genomics market is gradually becoming more competitive with new product
launches. For instance, in June 2022, PerkinElmer introduced an automated benchtop system for
NGS. The research used only BioQule NGS System to automate library preparation.
The service segment is expected to register a considerable CAGR by 2030. The high cost of
products, the demand for expertise required for genomics, and the focus on core operations by
the end user are the major factors driving the services segment. NGS-based services held a major
share in the genomics services segment due to the rapid adoption of Whole Genome Sequencing
(WGS) and applications of sequence databases for disorder screening and prognosis. However,
data processing and interpretation, rather than data production has become the need for current
development and application.
End-use Insights
The pharmaceutical and biotechnology companies segment led the market and accounted for a
revenue share of 57.3% in 2021. This is attributed to the increasing demand for use of genomics
in drug discovery. Moreover, the market is driven by novel therapeutic options like gene editing
and thereby the need for precision and personalized medicine. Numerous trials are underway for
novel drug discovery using underlying knowledge from genomics. For instance, in June 2022,
Illumina Inc., declares that it will present seven of their abstracts regarding the key oncology
research at the American Society of Clinical Oncology (ASCO) 2022 in further to an event to
discuss the transformational impact of comprehensive genomic profiling in precision medicine.

23
The hospital and clinic segment is estimated to grow at a substantial pace during the forecast
period. Several hospitals and clinics are currently offering genomic sequencing services to
patients and are determining the use of this technology in the daily practice of medicine. Stanford
Medicine is one such facility that provides genomic sequencing services to patients with a rare or
unidentified condition that is thought to be genetic. The first hospital system to offer the general
public services for genetic sequencing, analysis, and interpretation is Partners HealthCare based
in the U.S. It has enrolled over 200 patients and physicians in a study funded by NIH to study the
integration of whole genome sequencing in clinical medicine.
Regional Insights
North America accounted for the largest market share of 42.5% in 2021. This is attributed to the
support of research institutes and pharmaceutical giants. Genomics is now an integral part of any
disease research and drug discovery due to the implications of genetic expression on human
health. There are emerging advancements in the region for the utility of genomics with
collaborative efforts. For instance, in January 2022, Illumina, Inc. collaborates with Nashville
Biosciences, LLC, (part of Vanderbilt University Medical Center at Tennesee), for drug
development by using genomics and to establish a preeminent clinico-genomic resource.

24
Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to
increased demand for genomics applications in diagnostics and the growing demand for novel
therapeutic drugs to fight the increased incidence of diseases in the region. Several major human
genome sequencing projects are being performed, one of the most recent projects is Genome
Asia 100K. Under this project, 100,000 Asian genomes would be sequenced and analyzed, which
can help accelerate population-specific medical advances and precision medicine. With this
project, GA 100K was expected to identify new possible therapeutic drugs and understand the
biology of diseases.
Key Companies & Market Share Insights
Key players operating in the market are focused on strategic collaborations, new product
launches, and geographical expansions where needed in emerging and favorable regions across
the globe. For instance, in May 2022, Thermo Fisher Scientific declares collaboration with Qatar
Genome Program of the Qatar Foundation for the acceleration of research efforts in genomics
and its associative clinical applications in predictive genomics to benefit the global Arab
population by custom genotyping using the whole genome sequencing data from the 19 Arab
countries. Some of the prominent companies in the global genomics market include:
 Agilent Technologies
 Bio-Rad Laboratories, Inc.
 BGI Genomics
 Color Genomics, Inc.
 Danaher Corporation
 Eppendorf AG
 Eurofins Scientific
 F. Hoffmann-La Roche Ltd.
 GE Healthcare

25
  Illumina, Inc.
 Myriad Genetics, Inc.
 Oxford Nanopore Technologies
 Pacific Biosciences of California, Inc.
 QIAGEN N.V.
 Quest Diagnostics Incorporated
 Thermo Fisher Scientific, Inc.
 23andMe, Inc.
Genomics Market Report Scope
Report Attribute Details
Market size value in 2022 USD 28.1 billion
Revenue forecast in 2030 USD 94.9 billion
Growth rate CAGR of 16.4% from 2022 to 2030
Base year for estimation 2021
Historical data 2018 – 2020
Forecast period 2022 – 2030
Quantitative units Revenue in USD million and CAGR from 2022 to 2030
Revenue forecast, company ranking, competitive landscape,
Report coverage
growth factors, and trends
Segments covered Application & technology, deliverables, end-use, region
Regional scope North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan;
Country scope India; Australia; South Korea; Brazil; Mexico; Argentina; South
Africa; Saudi Arabia; UAE
Agilent Technologies, Bio-Rad Laboratories, Inc., BGI
Genomics, Color Genomics, Inc., Danaher Corporation,
Eppendorf AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd.,
Key companies profiled GE Healthcare, Illumina, Inc., Myriad Genetics, Inc., Oxford
Nanopore Technologies, Pacific Biosciences of California, Inc.
QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher
Scientific, Inc., 23andMe, Inc.
Free report customization (equivalent up to 8 analyst’s working
Customization scope days) with purchase. Addition or alteration to country, regional,
and segment scope.
Pricing and purchase options Avail customized purchase options to meet your exact research
needs. Explore purchase options

Global Genomics Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis
of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this

26
study, Grand View Research has segmented the global genomics market report on the basis of
application, deliverable, end-use, and region:

 Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)

 Functional Genomics

o Transfection
o Real-Time PCR
o RNA Interference
o Mutational Analysis
o SNP Analysis
o Microarray Analysis
Epigenomics
o Bisulfite Sequencing
o Chromatin Immunoprecipitation (ChIP & ChIP-Seq)
o Methylated DNA Immunoprecipitation (MeDIP)
o High-Resolution Melt (HRM)
o Chromatin Accessibility Assays
o Microarray Analysis
Pathway Analysis
o Bead-Based Analysis
o Microarray Analysis
o Real-time PCR
o Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)
Biomarker Discovery
o Mass Spectrometry
o Real-time PCR

27
 o Microarray Analysis
o Statistical Analysis
o Bioinformatics
o DNA Sequencing
Others
 Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)
 Products

o Instruments/Systems/Software
o Consumables & Reagents
Services
o NGS-based Services
o Core Genomics Services
o Biomarker Translation Services
o Computational Services
o Others
End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Clinical Research
Academic & Government Institutes
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other End Users
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
o U.S.
o Canada
Europe
o Germany
o U.K.
o France
o Italy
o Spain
Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
Latin America
o Brazil
o Mexico
o Argentina
Middle East & Africa
o South Africa
o Saudi Arabia
o UAE

28
 Chapter- 5
SWOT Analysis
The SWOT Analysis provides us with an excellent opportunity to examine and evaluate
the internal strengths and weakness of Genomids it also allow us to focus on the external
opportunities presented by the businesses’ environment as well as potential threats.
Next section explains major strengths, weakness, opportunities, and threats that Genomids
should be aware of:
STRENGTH
1. Economical treatments for our patents
2. Clear vision of the market needs.
3. Online services for small problems.
WEAKNESS
1. We are new in country.
2. Start-up challenges.
3. Certifications’ problems.
OPPORTUNITIES
1. Heterogeneous population growth of world.
2. No other competitors in India.
THREATS
1. Challenges of getting right gene for treatment.
2. Higher risk of post treatment issues.
3. Trust of peoples because we are new.

Chapter-6
Conclusion and Future enhancements
Promoting the use of genomics to maximize benefits and minimize harms
Genomics has been at the forefront of giving serious attention, through scholarly research and
policy discussions, to the impact of science and technology on society. Although the major
benefits to be realized from genomics are in the area of health, as described above, genomics can
also contribute to other aspects of society. Just as the HGP and related developments have
spawned new areas of research in basic biology and in health, they have also created
opportunities for research on social issues, even to the extent of understanding more fully how
we define ourselves and each other.
In the next few years, society must not only continue to grapple with numerous questions raised
by genomics, but must also formulate and implement policies to address many of them. Unless
research provides reliable data and rigorous approaches on which to base such decisions, those

29
policies will be ill-informed and could potentially compromise us all. To be successful, this
research must encompass both 'basic' investigations that develop conceptual tools and shared
vocabularies, and more 'applied', 'translational' projects that use these tools to explore and define
appropriate public-policy options that incorporate diverse points of view.

References
 Natures.com
 Grandviewresearch.com
 Dbtindia.com
 Biospace.com

THANK YOU

30